WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Metabolite Profiling and Analytical Challenges in Identifying and Quantifying Metabolites in Drug Development

Mudigonda Mallika[1] and Dr. A. Krishnamanjari Pawar[2]*

[1]Student, Department of Pharmaceutical Analysis, A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530003, Andhra Pradesh, India.

[2]Professor, Department of Pharmaceutical Analysis, A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530003, Andhra Pradesh, India.

ABSTRACT

Metabolite profiling is essential to contemporary medication development since it ensures the safety and effectiveness of therapeutic candidates and offers insights into the biotransformation of novel chemical entities (NCEs). The FDA and EMA's Metabolites in Safety Testing (MIST) guidelines are two regulatory frameworks that emphasize the importance of metabolite profiling. The functions of advanced analytical methods, such as imaging mass spectrometry, LC-MS, GC-MS, NMR spectroscopy, CE-MS, radiolabelling, and others, in detecting and measuring metabolites in intricate biological matrices are thoroughly examined. Difficulties involve low metabolite concentrations, matrix effects, isomeric interferences, a lack of reliable standards, metabolite instability, and inter-individual variability still exist despite tremendous advances in technology. High-resolution chromatographic and spectrometric techniques, surrogate standard development, pharmacogenomic integration of data, and sample preparation optimization are some of the strategies to get beyond these challenges. In order to obtain trustworthy metabolite data that support pharmacokinetic modelling, regulatory filings, and individualized therapeutic methods, these analytical obstacles must be removed. This review emphasizes how metabolite profiling is multidisciplinary and how important it is to safe, efficient, and scientifically sound medication development.

Keywords: Metabolite profiling, drug metabolism, LC-MS/MS, metabolomics, analytical challenges, pharmacokinetics, toxicology.

1. Introduction

The term "metabolomics" defines a general analytical approach for the identification and quantification of metabolites in biological systems. This research will seek differences among metabolites, obtain comprehensive metabolite profiles, and formulate theories to describe the differences. Metabolite analysis, especially metabolite profiling in biological samples that are challenging to analyze, is crucial to many life sciences. Metabolite profiling is a well-established concept. Mass spectrometry metabolic profiling was originally reported by Horning and Horning in 1971 In the same year, Pauling et al. analyzed breath vapor and urine using gas chromatography (GC) and compared the profiles to the results of a particular diet. The analyses of metabolites from various samples have been indispensable in the majority of research fields with the advent of various strong analytic methods, both chromatographic and spectroscopic. It is still hard to identify metabolites with absolute certainty despite the high sensitivity and resolution of numerous methods in such studies. [1,2,3,5,6]

Metabolomics is an interdisciplinary field that includes physiology, nutrition, microbiome analysis, exposomics, environmental evaluations, and biomarker identification. [7, 8] Quantitative metabolomics publications increased more than two-fold in the past eight years and exceeded 800 in 2023. The chemical nature of the analytes creates a number of challenges for quantitative metabolomics. Metabolites are endogenous molecules with molecular weights less than 1500 Da and varying physical and chemical properties. [7,9]

There are two major stages of drug metabolism: Phase II and Phase I. The prominent enzymes of Phase II metabolism include methyl transferase (MT), glutathione transferase (GST), sulfotransferase (SULT), UDP glucuronosyltransferase (UGT), and N-acetyltransferase (NAT). The prominent enzyme system for Phase I metabolism is cytochrome P450 (CYP).[10] The efficacy and safety of a drug to a significant extent depend on its metabolism.

Most functional metabolites that are stable exist in pharmacologically inactive forms during drug metabolism. In addition, metabolism also generates reactive metabolites that are potentially toxic. In the process of finding and designing new chemical entities (NCE) with acceptable safety attributes, different drug metabolic studies are conducted. It is the overall goal of the metabolic profiling experiments to find out the metabolites and pathways of participation in the biotransformation process. [11]

Some of the metabolites, such as lipids, are considerably less polar, but others, such as organic acids or amino acids, are small and strongly polar. Sensitive analytical techniques, such as nuclear magnetic resonance or liquid (or gas) chromatography coupled with mass spectrometry (LC-MS or GC-

MS), are needed to accurately quantify and accurately characterize such metabolites in such complicated biological specimens. [11,12,13, 14] Less specific analyses, e.g., high-resolution mass spectrometry, can also be used for absolute quantification. [15,16, 17,18]

2. TECHNIQUES USED FOR METABOLITE PROFILING

Many scientific disciplines, including integrated systems biology, biomarker identification, functional genomics, and studies of biological and environmental stress, have made use of metabolomics. To cover the entire spectrum of metabolites, several analytical platforms are required due to the metabolome's complexity and dynamic nature. The three most popular methods are mass spectrometry (MS), nuclear magnetic resonance (NMR), and Fourier transform infrared (FT-IR). [20,21,22,23,24]

A number of recent advances in technology in metabolite separation, detection, identification, and quantification have led to the collection of data that metabolomics seeks to combine. The identification and separation of metabolites have been regarded as crucial phases in metabolic profiling. Capillary electrophoresis (CE), gas chromatography (GC), and liquid chromatography (LC) in its high-performance (HPLC) or ultra-performance (UPLC) variants are the most often used separation methods. The most often used detection methods are nuclear magnetic resonance (NMR), mass spectrometry (MS), and near infrared spectroscopy (NIR). [25]

NMR [28], Fourier transform-infrared spectroscopy (FT-IR) [29,30], mass spectrometry (MS), and separation techniques, or direct flow injection. Among the many advantages of NMR are its potential for high-throughput fingerprinting, its low sample preparation requirements, and its non-destructive and non-discriminating nature. [26]

Since the quality of the experimental design and sample treatment determines the quality of the instrumental data, the entire metabolomics experiment should be organized as an integrated unit in addition to the analytical technique selection. Analyte separation and identification, data extraction and mining, sample collection and preparation, and data analysis are the four main components of a metabolomics experiment. [27]



Figure 1. General workflow for metabolomics analyses. Adapted from Saigusa et al., 2023

2.1 Sampling and Quenching

Sample collection is primarily dictated by the experiment's design and nature. A power analysis should be carried out, if at all possible, in order to guarantee that an adequate number of samples are collected, to lessen the impact of biological variability, and to produce statistically validated data. In the case of human samples, the effects of genetic variables, age, gender, and diet must be taken into account. Consequently, metabolic fingerprinting analysis frequently analyses a large number of samples in order to identify sample clustering that is biologically significant. Sample replicates, analytical replicates, blanks, including method blanks, and representative quality control samples must also be examined. Processing biological samples requires extra care to minimize the production or breakdown of metabolites following sampling because of residual oxidation or enzymatic activity.

2.2 Sample Preparation

For any analytical technique to be successful, sample preparation quality is a critical component. Usually, it has multiple uses. The primary objective is to extract the analytes from complex biological matrices, such as whole blood, serum, plasma, tissue homogenates, saliva, urine, cell pellets, or cell media, and to convert them into a format suitable for the analytical method while eliminating matrix components that might obstruct the analysis. A

pre-concentration phase may be incorporated into the extraction process for low-abundance metabolites in order to meet the analytical technique's detection limits.

A sample preparation procedure needs to be as simple and ubiquitous as feasible. It is important to remember that sample processing of any kind will result in analyte losses. Extraction techniques used on aqueous materials, in particular, will yield poor recoveries of highly polar chemicals. The following techniques can be used for sample preparation and introduction in biological sample analysis: direct injection, liquid-liquid extraction (LLE), solid-phase extraction (SPE), supercritical fluid extraction, accelerated solvent extraction, microwave-assisted extraction, protein precipitation, and membrane techniques like dialysis or ultracentrifugation. [26]

2.3 Separation and Detection of Metabolites

Mass spectrometry (MS) and nuclear magnetic resonance (NMR) are the two primary analytical tools utilized in metabolomics. Both instruments can measure a large number of metabolites in a high throughput and reproducible manner. [27]

2.3.1 High-performance liquid chromatography [HPLC]-

This commonly employed method allows for the separation of various chemicals by packing them into columns with 3–5 µm porous particles of a stationary phase that interact with them in diverse ways. However, using a traditional HPLC system to separate many components at the same time is quite challenging. Liquid chromatography is classified based on the stationary phase and on the mode of separation.

a] Adsorption chromatography, where an adsorbent (silica gel) acts as the stationary phase and the separation occurs due to repeated adsorption–desorption steps. There are two types of this type of chromatography: normal and reversed-phase chromatography, depending upon the relative polarity of the two phases. Normal phase chromatography employs a nonpolar mobile phase and a very polar stationary bed. Polar samples spend more time on the surface of the column packing than do less polar samples. Reversed-phase chromatography employs a polar liquid as the mobile phase and a nonpolar (hydrophobic) stationary bed, however, and the more nonpolar the substance, the more it will be retained.

b] In ion-exchange chromatography, ions in the sample are charged oppositely on the surface ionically charged stationary bed. Only ionic or ionizable samples are utilized using it. It will take longer for the sample to elute if its charge is stronger. The ionic strength and pH of the mobile phase, an aqueous buffer, regulate the elution time.

c] Size exclusion chromatography involves filling the column with material with controlled pore sizes, then screening or filtering the sample according to its solvated molecular size. Bigger molecules elute faster than smaller ones because the latter enter the porous structure of the packing particles and elute more slowly. While the stationary phase is no longer restricted to a "gel," this technique is also referred to as gel filtration or gel permeation chromatography. The basis of detection methods can be mass spectrometry (MS), fluorescence, evaporative light scattering, UV light, or refractive index. High-performance anion exchange chromatography (HPAEC) uses either pulsed amperometry detection or conductivity detection under ion suppression. [31]



Figure-2: Schematic overview of a high-performance liquid chromatography (HPLC) system [infusion pump, degasser, sampler/autosampler, chromatographic column, detector, and data processing unit], from Creative Proteomics Pronalyse HPLC service page.

2.3.2 Ultra-performance liquid chromatography [UPLC]-

Ultra-performance liquid chromatography [UPLC]: The rise of UPLC has led to recent technological developments in liquid chromatography. High pressure operations are made possible by advancements in pump systems that combine high working pressures with 1.7-µm porous particles packed in long capillary columns. Higher peak capacity, resolution, sensitivity, and speed are all provided by UPLC technology in comparison to HPLC. [32]

Similar results to those obtained with HPLC can be obtained with this method in a significantly shorter amount of time. According to [33] (2005), running durations could be shortened by ten times in this regard, indicating that UPLC is a viable analytical method for metabolomic studies. The same detectors used in traditional HPLC, including UV-VIS, fluorescence, and MS, are also used in UPLC. Although UPLC-MS technology is mostly used in pharmaceutical and bioanalysis research, it has also been used in food studies to identify dangerous substances, food additives, and food components. [31]



Fgure-3: Schematic overview of a UPLC- tandem mass spectrometry (UPLC-MS/MS) system, showing key components such as solvent reservoir, high- pressure pump, PFC isolator column, UPLC analytical column, tandem mass spectrometers, and data processing/display. Adapted from Taleuzzaman et al.

2.3.3 NMR Spectroscopy

- In order to conduct NMR spectroscopy, a chemical must be exposed to a magnetic field. The isotopes in the compound (e.g., 1H, 13C, 14N, 15N, and 17O) absorb the radiation and resonate at a unique frequency depending on their location inside the small molecule. [28] The resulting NMR spectrum is a collection of peaks at different positions and intensities, with a unique pattern for every chemical. In contrast to MS, NMR does not discriminate (any molecule with protons, carbon, nitrogen, or oxygen can be recognized), necessitates minimal sample preparation, and does not cause sample degradation while being analysed. One of the most significant benefits of NMR is probably its capacity to offer structural data that can be used to identify an unknown metabolite. One of NMR's primary drawbacks is its low sensitivity. [34] Since NMR-based approaches usually overlook low abundance metabolites, the metabolomics field has recently moved toward the use of more MS-based techniques. [26]



Figure 4: Workflow for NMR tracer-based metabolism: cell cultures are grown in a medium containing 13C- or 15N-labelled precursors…, from Saborano et al. [2019] Scientific Reports 9:2520.

2.3.4 MS –

The overall strategy for identifying target analytes by MS is outlined in Figure. The sample's biomolecules are separated and ionized using either gas chromatography (GC) or liquid chromatography (LC). MS determines the mass-to-charge (m/z) ratios of ions that are obtained by breaking down the

ionized parent chemical. Data collection software can be used to obtain a complete scan mass spectrum from target analytes. To find variations in important metabolites, bioinformatic methods can be used. Tandem mass spectrometry (MS/MS) is an alternative method for quantifying the analyte. Chemical ionization (CI) and electron impact ionization (EI) are methods for detecting and measuring biomolecules at sub-femtomole levels. High sensitivity, high selectivity, speed, and connectivity to GC or LC are the benefits of MS-based techniques. [35] Multiple sclerosis's main disadvantages are that it can be costly, selective (not all samples ionize in a given environment, and the source ion polarity may need to be adjusted), harmful to the sample, and typically requires sample processing, which can result in metabolite losses. [27]

2.3.5 Gas Chromatography/Mass Spectrometry [GC/MS]—

GC/MS is a widely used metabolomics tool that is effective in detecting volatile compounds such as fatty acids and organic acids. Because GC separation takes place in an oven at high temperatures, analytes must be volatile and thermally stable, and sample derivatization is frequently required before analysis. Although required, it is crucial to remember that one of the main disadvantages of GC/MS is that derivatization is an extra sample processing step that may cause metabolite loss. In GC/MS, EI or CI ionize samples as they enter the source. GC/MS can perform targeted and untargeted metabolomics by using the full scan and selective ion monitoring modes, respectively. To increase the sensitivity and separation of complicated metabolite mixtures, different techniques have recently been used. One of them, GC × GC, or "comprehensive GC," diverts each peak from a GC column to a second GC column in order to separate complex samples. By integrating GC or GC ×GC with a time of flight (TOF) mass analyser, mass accuracy (and hence chemical identification) can be enhanced. [36]

2.3.6 Liquid Chromatography/Mass Spectrometry [LC/MS]—

Biomedical mass spectrometry has evolved since electrospray ionization (ESI) was developed, allowing the coupling of mass spectrometry (MS) and liquid chromatography (LC). Metabolomics is currently the main application for this technology. The metabolome's extensive coverage is one of the main challenges in LC/MS. Reversed phase LC and C18 columns are commonly used and provide good separation of weakly polar and nonpolar substances. However, polar analytes are not retained by these C18 columns. Tolstikov and Fiehn recently presented hydrophilic interaction chromatography (HILIC), a unique type of LC for examining polar chemicals in plant extracts. HILIC columns, which employ modified stationary phases, employ reversed phase LC, but they specifically retain polar chemicals that elute as the mobile phase becomes more aqueous. HILIC has some drawbacks despite its benefits, such as poor repeatability of retention time and analytical drift when analyzing many samples. Lipids and other non-polar substances are commonly subjected to atmospheric pressure chemical ionization (APCI). For lipid species that are thermally stable, APCI is a reliable ionization method that produces minimal fragmentation and maintains the molecular ion. Capillary LC and nano-LC with low flow rates offer remarkable dynamic range and sensitivity when paired with ESI and APCI. Nowadays, metabolomic research uses these methods, which were widely utilized in proteomics. The resulting microdroplets improve chromatographic resolution and mass analyzer detection while requiring less time for evaporation. Recent applications of Matrix Assisted Laser Desorption Ionization (MALDI) include the study of amino acids and metabolites from bacterial cells and islets. [40, 41] However, MALDI has significant limitations, including matrix interference for low-molecular-weight compounds and ion suppression.

Metabolomic research based on LC/MS can employ a variety of mass analysers. The most used analyzers for metabolomic studies are quadrupole, ion trap, and time of flight (TOF) based analyzers. Other kinds are orbitraps and Fourier Transform (FT) MS. By sequentially joining three quadrupoles, the triple quadrupole (QQQ) makes MS/MS possible. When used with multiple reaction monitoring (MRM), the QQQ can be used to experimentally confirm potential biomarkers. An ion-trap mass analyzer may focus on a group of ions with a certain m/z, just like a QQQ. Ion-traps have the ability to do a multistep MS/MS, sometimes referred to as MSn, in which a specific fragment ion is stored in the chamber and repeatedly disassociated. [27]



Figure-5: Analytical workflow for metabolomics in systems biology. Adapted from Smith et al., 2010

2.3.7 High-resolution Mass Spectrometry-

Numerous analytical domains have greatly benefited from the use of high-resolution (HR) MS. The majority of applications make use of the strong accuracy of contemporary instruments to perform unsupervised searches or catalog the ions that are present in a particular sample. The identification of unknown proteins [43] and protein modification [44,45,46], peptide mapping [47,48], metabonomics [49], and biomarker discovery [50] are a few instances of how HR-MS affects these kinds of applications. There are numerous parallels between the use of HR-MS technology in drug metabolism and applications in fields like doping control and forensic science. [51,52,53]

When determining the empirical formulas of metabolites or their fragments was necessary, HR-MS devices were used. [55,56,57] This comprehensive technique requires a number of instruments and repeated MS tests, yet it was successful in understanding unexpected metabolites. [56,58] New and enhanced HR-MS instruments [35,36,37,38] and data processing methods [54,63-73] have been developed for metabolite identification in the last 6–8 years. Because of this, HRMS devices can now perform all necessary metabolite identification tasks with much higher quality and productivity [68,72–75] [42]



Figure-6: Generalized workflow for drug metabolite profiling via high-resolution mass spectrometry. Adapted from Zhu *et al.*, 2011.

3. CHALLENGES OF METABOLOMICS ANALYSIS

The metabolome may be affected by a number of genetic and environmental factors. Therefore, in order to minimize variables and maximize information recovery, a number of factors must be taken into account when conducting a metabolomic investigation. Reducing interindividual variance requires improving experimental design, and choosing the best analytical platform for the experiment or laboratory is crucial because both might impact the experiment's outcome and data recovery. Identifying the biomarkers is another drawback of metabolomics, especially when it comes to LC-MS-based metabolomics. [76]

3.1 Pre-Analytical Challenges

Measures should be taken to assure that the samples are chosen and handled appropriately before the method measuring the analyte of interest is analytically validated. If pre-analytical factors are not taken into account, confounders may be introduced into the results, which would lower the analytical method's perceived accuracy and reproducibility. [78] Both targeted and untargeted metabolomics techniques based on LC-MS can face these pre-analytical difficulties. Since the effect on the entire metabolome is unknown, these factors should be avoided for untargeted metabolomics. The effect of these pre-analytical parameters on the target metabolites should be examined in a targeted metabolomics investigation, particularly when validating an analytical method, to guarantee appropriate sample handling and procurement.

3.1.1 Patient Selection

Environmental and genetic variables are among the many sources that impact the metabolome, which is always changing. [80, 81, 83] Environmental contaminants, medications, lifestyle choices, and food are examples of these environmental influences. [82, 83] The metabolome can be altered by environmental factors such as nutrition and smoking. It has been discovered that smoking cigarettes changes the metabolome and related metabolites, and that smoking is linked to body mass index (BMI). [79] Even while every patient sample will naturally differ metabolically, confounders such medications and comorbidities must be kept to a minimum because they might significantly affect the analytes of interest. It is crucial to reduce the effects of confusing factors wherever possible, even though it is impossible to regulate every possible source.

3.1.2 Sample Collection and Storage

Once patients who meet your inclusion and exclusion criteria have been chosen, samples must be gathered and kept in a systematic way until they are needed. The quality of the samples will be affected by the collecting and storage methods. It is crucial to make sure that the standard operating procedures (SOPs) are created specifically for metabolomics analysis and that they are adhered to. Otherwise, metabolomic analysis may be highly variable due to improper sample treatment, metabolite degradation, and other reasons.

Reagents like anticoagulants can affect a metabolomics study's outcome. Different storage containers and vials can be built of different materials, which can have varied effects on the metabolome, much as the concepts underlying various anticoagulants for plasma collection. One can skip the clotting time when dealing with plasma samples. But in order to keep blood from coagulating, it needs to be drawn in tubes containing anticoagulation agents such sodium citrate, heparin, or ethylenediaminetetraacetic acid (EDTA). [84, 85] Research has indicated notable variations in the expression of triglycerides, cholesterol, and other lipid species across plasma samples treated with sodium citrate or EDTA. [86] Additionally, it has been discovered that anticoagulants may cause matrix effects that change the quantities of metabolites observed; these effects may increase, decrease, or completely eliminate the detection of metabolites. [85,86] Therefore, it is advised to collect plasma samples using the same anticoagulant and to make sure that any experimental reagents added do not cause ion suppression or boost your target analytes. [77]

3.2 Analytical Challenges in Drug Metabolite Profiling

3.2.1 Low Concentrations and Matrix Effects

Metabolites are hard to detect as they usually occur in biological matrices such as plasma, urine, or bile at nanomolar concentrations. Endogenous metabolites may suppress or enhance ionization in mass spectrometry and co-elute during chromatographic separation, thus resulting in precise measurement. These issues are to be avoided and sufficient analytical performance attained with correct sample preparation, estimation of matrix effect, and use of proper internal standards.

3.2.2 Lack of Authentic Standards

Metabolite measurement accuracy is influenced by the unavailability of robust reference standards, particularly at early stages of development. Surrogate quantitation with the parent drug can cause major bias due to variations in ionization efficiency and matrix effects. Stable isotope-labelled internal standards or highly validated surrogate analytes can enhance measurement robustness and regulatory acceptability.

3.2.3 Complex Biological Matrices:

There are thousands of endogenous metabolites in biological specimens (e.g., plasma, urine, and tissues), so it is a challenge to locate commonly low-abundance drug metabolites hidden in such complex backgrounds.

3.2.4 Low Metabolite Concentrations and Wide Dynamic Range:

The fact that drug metabolites exist in very small amounts (e.g., nanomolar) requires highly sensitive analytical equipment capable of detecting traces of endogenous molecules amidst a sea of others.

3.2.5 Structural Complexity and Unknown Metabolites:

A single analytical technique is rarely adequate to afford the extensive structural elucidation that is required for new or unanticipated metabolites. Orthogonal methods will often need to be employed since fragmentation patterns are not always definitive.

3.2.6 Instrumental Variability and Data Quality:

The most important platform, liquid chromatography–mass spectrometry (LC-MS), is prone to matrix-induced ion suppression, batch effects, and experimental drift, all of which can bias metabolite identification and quantification in the absence of rigorous quality control (QC). [87]

3.2.7 Incomplete Metabolite Coverage:

Chemical complexity precludes the analysis of all the metabolites by one type of analysis. For comprehensive profiling, multi-platform-based combined techniques are required due to differences in biases and sensitivities of different platforms. [88]

4. STRATEGIES TO OVERCOME ANALYTICAL CHALLENGES

The U.S. Food and Drug Administration [FDA) published a formal advice on metabolite safety testing criteria [MIST) in February 2008. One It is important to pay attention to three assertions in the FDA guidance: In general, while evaluating safety, metabolites that are exclusively present in human plasma or that are present in humans at disproportionately greater levels than in any of the animal test species should be taken into account; 3) As early as possible in the drug development process, human in vivo metabolic evaluation is strongly advised; and 4) human metabolites that can cause safety concerns are those that generate at more than 10% of the parent drug's systemic exposure at steady state. The International Conference on Harmonization [ICH) subsequently established that 10% of the total exposure linked to the drug is the level of a metabolite needed for nonclinical safety testing. [89, 90]

4.1. Use of Complementary Analytical Platforms

4.1.1 High-Resolution LC-MS [HR-LC-MS]:

High sensitivity and precise mass measurements are provided by HR-LC-MS, the foundation of metabolite profiling, to differentiate compounds from endogenous background. Both anticipated and unanticipated metabolites can be detected using data acquisition modes including full-scan MS and data-dependent MS/MS with sophisticated data mining. [87]

4.1.2 Gas Chromatography–Mass Spectrometry [GC-MS]:

useful for volatile and derivatized metabolites (such organic acids and amino acids) . It offers a large metabolite library to facilitate identification and excellent chromatographic resolution. [91]

4.1.3 Nuclear Magnetic Resonance [NMR] Spectroscopy:

it offers extremely reproducible, structurally descriptive, and non-destructive information that is especially valuable in the identification and quantitation of abundant metabolites. By detecting metabolites that MS would find challenging to determine on its own, NMR complements MS methods. [92]

4.1.4 Hybrid Techniques [e.g., HPLC-NMR]:

used to provide extensive structural elucidation when metabolite structures cannot be definitively resolved using normal MS or NMR techniques. [87]

4.1.5 Additional Methods:

Direct infusion MS (DI-MS) and capillary electrophoresis-MS (CE-MS) can increase coverage for polar or quickly screened compounds, but they have drawbacks including complicated data interpretation or ion suppression effects. [87]

4.2. Robust Quality Control and Data Validation

4.2.1 Randomization:

The samples' randomized order analysis is required to lessen the systematic bias brought on by temporal instrument drift. [87]

4.2.2 Quality Control [QC] Samples:

Instrument performance is monitored by regularly analyzing pooled matrix samples or standard metabolites during runs. Multivariate statistical approaches are used to evaluate QC data in order to identify any problems or batch effects that could invalidate the results. [87]

4.2.3 Statistical QC Assessment:

Prior to biological interpretation, clustering of QC sample data without time trends shows consistent instrument performance and data validity. [93]

4. 3. Optimized Sample Preparation and Enrichment

4.3.1 Solid-Phase Extraction [SPE] or Similar Techniques:

improves detection sensitivity, enriches target metabolites, and lowers matrix complexity. [87]

4.3.2 Chemical Derivatization:

increases detectability by enhancing the thermal stability and volatility of certain metabolites to facilitate GC-MS analysis. [91]

4.4. Iterative and Integrated Profiling Approaches

- It is possible to thoroughly identify minor, active, or dangerous metabolites by beginning metabolite profiling early in drug development and iteratively evaluating metabolites at various stages. [94]

5. APPLICATIONS

Although metabolomic applications are heavily emphasized in later phases of drug discovery, such as clinical trials, early discovery - which includes fields like target validation and high-throughput screening (HTS) - represents the costliest aspect of pharmaceutical development. The earliest phases of drug research may be the most cost-effective times to apply attrition reduction strategies. [95, 96] The primary uses of metabolomics in drug discovery have been in the following areas:

- Chemical library testing;
- High throughput natural product analysis;
- Analyzing metabolic networks computationally.

Furthermore, metabolomics has been demonstrated to be a valuable technique for tracking dietary or behavioural (e.g., drug or alcohol use) compliance [100–102], monitoring drug utilization with analysis of patient compliance of adherence [99], analyzing therapeutic response which provides markers of disease or drug application or toxicity [103,104], stratifying patients and theragnostic [105–107], and determining drug dose or individual drug metabolism [98,108-110]. [97]

5.1 Metabolomics in natural product discovery and analysis

Natural products - chemical compounds or substances made by living things, such as metabolites - offer a conventional source of lead molecules in drug development because of their bioactivity and structural variety. [111] Natural products can be employed directly or as structural scaffolds to create analogues with better safety and pharmacological potency. Individual, bioactive metabolites are the focus of natural product discovery, whereas metabolomics attempts to derive meaning from intricate databases of metabolic mixtures. Metabolomics and natural product analysis share the goal of metabolite identification and employ the same analytical methodologies, despite their historical differences. When it comes to analyzing complicated mixtures of metabolites, metabolomics is a comprehensive technique that aims to analyse known and unknown substances in biological samples—metabolite mixtures - objectively and at high throughput. [114] Approximately 170,000 distinct plant secondary metabolites have been listed in the Dictionary of Natural Products to far. [111] In spite of the enormous number of known metabolites, the great majority of metabolites in the diverse range of biological systems have not been well studied. Since metabolomics would enable the examination of complicated mixtures, such phytochemical preparations, without requiring the isolation of individual chemicals, Advances in this area are expected to revive interest in high throughput natural product analysis. Clustering and grouping samples are the foundation of the main metabolomics data analysis techniques. Extracts from various sources or with varying activity can be directly compared using high dimensional measurements of natural product mixes. Without first separating the metabolites, multivariate data analysis techniques for both unsupervised and supervised analysis can be utilized to identify similarities and differences between samples of various activities.

5.2 Metabolomics in chemical libraries testing

Chemical libraries are collections of stored compounds that are either targeted or untargeted and are compiled from natural product libraries or synthesized using different kinds of combinatorial chemistry. A range of high-throughput screening techniques are used to test these massive chemical assemblages in order to identify subsets of molecules of interest for specific uses. Biological or chemical tests can effectively measure the effects of agents or circumstances thanks to high-throughput screening techniques. For these techniques to boost test speed and scale, robotics, imaging, and computation are frequently needed. Thus, fewer drug candidates are found and chosen from libraries according to their chemical characteristics and high-throughput screening efficacy. Lipinski's rule of five properties can be used to predict a compound's drug-likeness in the library. [115] Drug properties can be more precisely predicted by the absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis of medications. This information can be used to pre-select medications from libraries. [116,117] Metabolomics analysis can be used to improve the investigation of ADMET properties for several chemicals and to provide molecular information. The application of metabolomics analysis to toxicology testing has included examining potential toxins generated by a drug's metabolism as well as the mechanisms of action that result in drug toxicity. [103, 107, 108]

5.3 Metabolomics and metabolism modelling in optimization of drug discovery [and preparation]

Models of cell metabolic networks and pathways have become increasingly sophisticated thanks to the widespread usage of metabolomics data in conjunction with other omics data. These networks can be used to better produce a range of small molecules (drugs, bio actives) or proteins (bioimmunes, for example), as well as identify key targets within various cell phenotypes and the metabolites that interact with these targets, which can serve as inspiration for new drug development. Information regarding the ideal development and behaviour of cells under various settings and gene

alterations can be obtained using in silico metabolic modelling based on genome-wide models. [118,119] This method has already shown promise in identifying leads for the development of pharmacological targets [120–122] and in optimizing the manufacturing of bioreactors. [123–125]

5.4 Other applications – metabolic biomarkers of drug function and theragnostics

The greatest potential for metabolomics contribution to health care is in determination of disease markers and their detection. [127] Either the same or different groups of metabolites can be used as markers of drug efficacy either in organisms or in cells or enzymatic assays used in testing new drug leads. Metabolomics analysis of various biological fluids and tissue samples can have a role in clinical and surgical practice from prognostic, through diagnostic, treatment planning and monitoring to recovery, rehabilitation or critical care. [128] Individual metabotypes, i.e. metabolic profiles in body fluids of an individual, are related to disease risk factors as well as treatment outcomes, providing an interesting avenue for personalized medicine [129–131]. Drug or food interactions, individual differences, disease stage and type, patient behaviour, general health, etc. are all important elements that affect a safe and effective drug dosage. In light of the growing issue of drug overdose in individual individuals, metabolomics can offer a method for objectively tracking the levels of drugs and drug metabolites in bodily fluids to establish the best dosages for each case. Unbiased monitoring can also reveal details regarding a patient's potential drug toxicity and reactions. Numerous articles have already demonstrated how to trace both illegal and prescription drugs using metabolomics. [126] The FDA offered a preliminary viewpoint on the application of omics technologies, such as metabolomics, in assessing the safety of novel medications in 2009. Since these early viewpoints, metabolomics has been widely applied in drug safety assessment in animal models. For example, Jeong et al. [101] and Mattes et al. have examined metabolic markers of liver injury in rats. [128] Recently, Weiler et al. [103], have provided numerous examples of biomarker analysis, including metabolic markers of drug-induced liver impairment.

6. CONCLUSION:

Metabolomics is a strong and crucial technology of contemporary life sciences and drug discovery with deep perception of metabolites in different biological systems. By using advanced analytical techniques like NMR, LC-MS, GC-MS, and high-resolution mass spectrometry, researchers can identify, measure, and get a vision of the dynamics of the metabolites involved in the physiological, pathological, and pharmaceutical processes.

Metabolomics is confronted with numerous challenges to its efforts in revolutionizing the field. These are short metabolite coverage, matrix effect, issues of sample handling and storage, run-to-run analysis variation, and insufficient standards. Yet, these obstacles can sufficiently be handled by taking proper quality control, employing complementary analysis platforms, iterative profiling protocols, and proper experimental design.

Metabolomics integrates a broad range of applications including metabolic modeling, ADMET prediction, personalized medicine, and natural product discovery and screening of chemical libraries. Metabolomics has become a core pillar for target-based precision drug discovery and development because it is capable of identifying metabolic biomarkers, determining drug efficacy and toxicity, and informing theragnostic deployment.

Metabolomics will more and more be a critical driver in further refining our knowledge of complex biological systems, in directing therapeutic interventions, and allowing for safer and more effective drug development pipelines as analytics evolve and interface with computation platforms and multi-omics.

REFERENCES:

1. Wolfender JL, Marti G, Thomas A, Bertrand S. Current approaches and challenges for the metabolite profiling of complex natural extracts. Journal of Chromatography a. 2015 Feb 20; 1382:136-64.
2. Sumner LW, Mendes P, Dixon RA. Plant metabolomics: large-scale phytochemistry in the functional genomics era. Phytochemistry. 2003 Mar 1;62[6]:817-36.
3. van der Greef J, van Wietmarschen H, van Ommen B, Verheij E. Looking back into the future: 30 years of metabolomics at TNO. Mass spectrometry reviews. 2013 Sep;32[5]:399-415.
4. Horning EC, Horning MG. Human metabolic profiles obtained by GC and GC/MS. Journal of Chromatographic Science. 1971 Mar 1;9[3]:129-40.
5. Glauser G, Guillarme D, Grata E, Boccard J, Thiocone A, Carrupt PA, Veuthey JL, Rudaz S, Wolfender JL. Optimized liquid chromatography–mass spectrometry approach for the isolation of minor stress biomarkers in plant extracts and their identification by capillary nuclear magnetic resonance. Journal of Chromatography A. 2008 Feb 8;1180[1-2]:90-8.
6. Creek DJ, Dunn WB, Fiehn O, Griffin JL, Hall RD, Lei Z, Mistrik R, Neumann S, Schymanski EL, Sumner LW, Trengove R. Metabolite identification: are you sure? And how do your peers gauge your confidence? Metabolomics. 2014 Jun;10[3]:350-3.
7. Ghafari, N., & Sleno, L. [2024]. Challenges and recent advances in quantitative mass spectrometry-based metabolomics. *Analytical science advances*, *5*[5-6], e2400007. https://doi.org/10.1002/ansa.202400007
8. Aderemi, A. V., Ayeleso, A. O., Oyedapo, O. O., & Mukwevho, E. [2021]. Metabolomics: A Scoping Review of Its Role as a Tool for Disease Biomarker Discovery in Selected Non-Communicable Diseases. *Metabolites*, *11*[7], 418. https://doi.org/10.3390/metabo11070418

9. Kuehnbaum NL, Britz-McKibbin P. New advances in separationscience for metabolomics: Resolving chemical diversity in a post-genomic era. Chem Rev. 2013;113[4]:2437-2468 https://doi.org/10.1021/cr300484s

10. Gonzalez FJ, Tukey RH. Drug metabolism. Goodman and Gilman's. The Pharmacological Basis of Therapeutics. 11ª ed. McGraw-Hill. 2006:71-91.

11. Muhamad, N., & Na-Bangchang, K. [2020]. Metabolite Profiling in Anticancer Drug Development: A Systematic Review. *"Drug Design, Development and Therapy*, *14*, 1401–1444. https://doi.org/10.2147/DDDT.S221518

12. Thakkar H, Gangakhedkar S, Shah RP. Bioanalysis of stress biomarkers through sensitive HILIC-MS/MS method: a stride toward accurate quantification of MDA, acr, and CTA. Journal of the American Society for Mass Spectrometry. 2024 Apr 26;35[6]:1110-9.

13. Qian X, Liu W, Chen Y, Zhang J, Jiang Y, Pan L, Hu C. A UPLC-MS/MS method for simultaneous determination of arachidonic acid, stearic acid, and related endocannabinoids in human plasma. Heliyon. 2024 Apr 15;10[7].

14. Németh K, Szatmári I, Tőkési V, Szabó PT. Application of Normal-Phase Silica Column in Hydrophilic Interaction Liquid Chromatography Mode for Simultaneous Determination of Underivatized Amino Acids from Human Serum Samples via Liquid Chromatography–Tandem Mass Spectrometry. Current Issues in Molecular Biology. 2023 Nov 22;45[12]:9354-67.

15. Gao S, Wang X, Huang J, Zhu Y, Zhang R, He J, Abliz Z. Development and validation of a sensitive and reliable targeted metabolomics method for the quantification of cardiovascular disease-related biomarkers in plasma using ultrahigh-performance liquid chromatography–tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 2022 Jun 30;36[12]: e9292.

16. Mrowiec K, Debik J, Jelonek K, Kurczyk A, Ponge L, Wilk A, Krzempek M, Giskeødegård GF, Bathen TF, Widłak P. Profiling of serum metabolome of breast cancer: multi-cancer features discriminate between healthy women and patients with breast cancer. Frontiers in Oncology. 2024 Apr 4; 14:1377373.

17. Lai Z, Choudhury FK, Tang D, Liang X, Dean B, Misaghi S, Sangaraju D. LC-HRMS-based targeted metabolomics for high-throughput and quantitative analysis of 21 growth inhibition-related metabolites in Chinese hamster ovary cell fed-batch cultures. Biomedical Chromatography. 2022 May;36[5]: e5348.

18. Dmitrieva E, Temerdashev A, Azaryan A, Gashimova E. Quantification of steroid hormones in human urine by DLLME and UHPLC-HRMS detection. Journal of Chromatography B. 2020 Nov 30; 1159:122390.

19. Lefeuvre S, Bois-Maublanc J, Mongeois E, Policarpo V, Formaux L, Francia T, Billaud EM, Got L. Quantitation using HRMS: A new tool for rapid, specific and sensitive determination of catecholamines and deconjugated methanephrines metanephrines in urine. Journal of Chromatography B. 2021 Mar 1; 1166:122391.

20. Xiao, J. F., Zhou, B., & Ressom, H. W. [2012]. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. *Trends in analytical chemistry: TRAC*, *32*, 1–14. https://doi.org/10.1016/j.trac.2011.08.009

21. Rosenblum ES, Viant MR, Braid BM, Moore JD, Friedman CS, Tjeerdema RS. Characterizing the metabolic actions of natural stresses in the California red abalone, Haliotis rufescens using 1H NMR metabolomics. Metabolomics. 2005 Apr;1[2]:199-209.

22. Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner HP. Targeted metabolomics for biomarker discovery. Angewandte Chemie International Edition. 2010 Jul 26;49[32]:5426-45.

23. Saito K, Matsuda F. Metabolomics for functional genomics, systems biology, and biotechnology. Annual review of plant biology. 2010 Jun 2;61[1]:463-89.

24. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends in biotechnology. 1998 Sep 1;16[9]:373-8.

25. Mozzi F, Ortiz ME, Bleckwedel J, De Vuyst L, Pescuma M. Metabolomics as a tool for the comprehensive understanding of fermented and functional foods with lactic acid bacteria. Food Research International. 2013 Nov 1;54[1]:1152-61.

26. Dettmer, K., Aronov, P. A., & Hammock, B. D. [2007]. Mass spectrometry-based metabolomics. *Mass spectrometry reviews*, *26*[1], 51–78. https://doi.org/10.1002/mas.20108

27. Wang, J. H., Byun, J., & Pennathur, S. [2010]. Analytical approaches to metabolomics and applications to systems biology. *Seminars in nephrology*, *30*[5], 500–511. https://doi.org/10.1016/j.semnephrol.2010.07.007

28. Nicholson JK, Wilson ID. Understanding'global'systems biology: metabonomics and the continuum of metabolism. Nature Reviews Drug Discovery. 2003 Aug 1;2[8]:668-76.

29. Harrigan GG, LaPlante RH, Cosma GN, Cockerell G, Goodacre R, Maddox JF, Luyendyk JP, Ganey PE, Roth RA. Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicology letters. 2004 Feb 2;146[3]:197-205.

30. Johnson HE, Broadhurst D, Kell DB, Theodorou MK, Merry RJ, Griffith GW. High-throughput metabolic fingerprinting of legume silage fermentations via Fourier transforms infrared spectroscopy and chemometrics. Applied and Environmental Microbiology. 2004 Mar;70[3]:1583-92.

31. Toyo'oka T. [2008]. Determination methods for biologically active compounds by ultra-performance liquid chromatography coupled with mass spectrometry: application to the analyses of pharmaceuticals, foods, plants, environments, metabonomics, and metabolomics. *Journal of chromatographic science*, *46*[3], 233–247. https://doi.org/10.1093/chromsci/46.3.233

32. Wren S. A. [2005]. Peak capacity in gradient ultra performance liquid chromatography [UPLC]. *Journal of pharmaceutical and biomedical analysis*, *38*[2], 337–343. https://doi.org/10.1016/j.jpba.2004.12.028

33. Wilson, I. D., Plumb, R., Granger, J., Major, H., Williams, R., & Lenz, E. M. [2005]. HPLC-MS-based methods for the study of metabonomics. *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences*, *817*[1], 67–76. https://doi.org/10.1016/j.jchromb.2004.07.045

34. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007;387[2]:525–527. [PubMed: 16955259]

35. Bain JR, Stevens RD, Wenner BR, et al. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 2009;58[11]:2429–2443.

36. Humston EM, Zhang Y, Brabeck GF, McShea A, Synovec RE. Development of a GC × GC-TOFMS method using SPME to determine volatile compounds in cacao beans. J Sep Sci 2009;32[13]:2289–2295. [PubMed: 19569109]

37. Grandori R, Santambrogio C, Brocca S, Invernizzi G, Lotti M. Electrospray-ionization mass spectrometry as a tool for fast screening of protein structural properties. Biotechnol J 2009;4[1]:73–87. [PubMed: 19156745]

38. Ho C, Lam C, Chan M, et al. Electrospray ionisation mass spectrometry: principles and clinical applications. Clin Biochem Rev 2003;24[1]:3–12. [PubMed: 18568044]

39. Tolstikov VV, Fiehn O. Analysis of highly polar compounds of plant origin: combination of hydrophilic interaction chromatography and electrospray ion trap mass spectrometry. Anal Biochem 2002;301[2]:298–307. [PubMed: 11814300]

40. Edwards JL, Kennedy RT. Metabolomic analysis of eukaryotic tissue and prokaryotes using negative mode MALDI time-of-flight mass spectrometry. Anal Chem 2005;77[7]:2201–2209. [PubMed:15801754]

41. Dally JE, Gorniak J, Bowie R, Bentzley CM. Quantitation of underivatized free amino acids in mammalian cell culture media using matrix assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem 2003;75[19]:5046–5053. [PubMed: 14708777]

42. Zhu, M., Zhang, H., & Humphreys, W. G. [2011]. Drug metabolite profiling and identification by high-resolution mass spectrometry. *The Journal of biological chemistry*, *286*[29], 25419–25425. https://doi.org/10.1074/jbc.R110.200055

43. Zhang H, Cui W, Wen J, Blankenship RE, Gross ML. Native electrospray and electron-capture dissociation in FTICR mass spectrometry provide top-down sequencing of a protein component in an intact protein assembly. Journal of the American Society for Mass Spectrometry. 2011 Feb 25;21[12]:1966-8.

44. Lourette N, Smallwood H, Wu S, Robinson EW, Squier TC, Smith RD, Paša-Tolić L. A top-down LC-FTICR MS-based strategy for characterizing oxidized calmodulin in activated macrophages. Journal of the American Society for Mass Spectrometry. 2010 Jun;21[6]:930-9.

45. Wu S, Tolić N, Tian Z, Robinson EW, Paša-Tolić L. An integrated top-down and bottom-up strategy for characterization of protein isoforms and modifications. InBioinformatics for Comparative Proteomics 2010 Nov 1 [pp. 291-304]. Totowa, NJ: Humana Press.

46. Tipton JD, Carter JD, Mathias JD, Emmett MR, Fanucci GE, Marshall AG. Sequential proteolysis and high-field FTICR MS to determine disulfide connectivity and 4-maleimide TEMPO spin-label location in L126C GM2 activator protein. Analytical chemistry. 2009 Sep 15;81[18]:7611-7.

47. Nilsson T, Mann M, Aebersold R, Yates III JR, Bairoch A, Bergeron JJ. Mass spectrometry in high-throughput proteomics: ready for the big time. Nature methods. 2010 Sep;7[9]:6815.

48. Papasotiriou DG, Jaskolla TW, Markoutsa S, Baeumlisberger D, Karas M, Meyer B. Peptide mass fingerprinting after less specific in-gel proteolysis using MALDI-LTQ-Orbitrap and 4-chloro-α-cyanocinnamic acid. Journal of proteome research. 2010 May 7;9[5]:2619-29.

49. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clinical cancer research. 2009 Jan 15;15[2]:431-40.

50. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Advances in Cancer Research. 2006 Jan 1; 96:23-50.

51. Maurer HH. Perspectives of liquid chromatography coupled to low-and high-resolution mass spectrometry for screening, identification, and quantification of drugs in clinical and forensic toxicology. Therapeutic drug monitoring. 2010 Jun 1;32[3]:324-7.

52. Jiwan JL, Wallemacq P, Hérent MF. HPLC-high resolution mass spectrometry in clinical laboratory? Clinical biochemistry. 2011 Jan 1;44[1]:136-47.

53. Thevis M, Thomas A, Kohler M, Beuck S, Möller I, Schäfer M, Rodchenkov G, Yin S, Loo JA, Geyer H, Schänzer W. Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis. European Journal of Mass Spectrometry. 2010 Jun;16[3]:301-12.

54. Zhu M, Ma L, Zhang D, Ray K, Zhao W, Humphreys WG, Skiles G, Sanders M, Zhang H. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug metabolism and disposition. 2006 Oct 1;34[10]:1722-33.

55. Zhang N, Fountain ST, Bi H, Rossi DT. Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC/MS. Analytical chemistry. 2000 Feb 15;72[4]:800-6.

56. Ma S, K Chowdhury S, B Alton K. Application of mass spectrometry for metabolite identification. Current drug metabolism. 2006 Jul 1;7[5]:503-23.

57. Chen G, Daaro I, Pramanik BN, Piwinski JJ. Structural characterization of in vitro rat liver microsomal metabolites of antihistamine desloratadine using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange HR-LC/MS. Journal of mass spectrometry. 2009 Feb;44[2]:203-13.

58. Prakash C, Shaffer CL, Nedderman A. Analytical strategies for identifying drug metabolites. Mass spectrometry reviews. 2007 May;26[3]:340-69.

59. Perry RH, Cooks RG, Noll RJ. Orbitrap mass spectrometry: instrumentation, ion motion and applications. Mass spectrometry reviews. 2008 Nov;27[6]:661-99.

60. Bristow AW. Accurate mass measurement for the determination of elemental formula—a tutorial. Mass spectrometry reviews. 2006 Jan;25[1]:99-111.

61. Sanders M, A Shipkova P, Zhang H, M Warrack B. Utility of the hybrid LTQ-FTMS for drug metabolism applications. Current drug metabolism. 2006 Jul 1;7[5]:547-55.

62. Bristow T, Constantine J, Harrison M, Cavoit F. Performance optimisation of a new-generation orthogonal-acceleration quadrupole-time-of-flight mass spectrometer. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass Spectrometry. 2008 Apr 30;22[8]:1213-22.

63. Zhang H, Zhang D, Ray K. A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. Journal of Mass Spectrometry. 2003 Oct;38[10]:1110-2.

64. Wrona M, Mauriala T, Bateman KP, Mortishire-Smith RJ, O'Connor D. 'All-in-one'analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass Spectrometry. 2005 Sep 30;19[18]:2597-602.Zhang H., Yang Y. [2008] J. Mass Spectrom. 43, 1181–1190

65. Zhang H, Yang Y. An algorithm for thorough background subtraction from high-resolution LC/MS data: Application for detection of glutathione-trapped reactive metabolites. Journal of mass spectrometry. 2008 Sep;43[9]:1181-90.

66. Wrona M, Mauriala T, Bateman KP, Mortishire-Smith RJ, O'Connor D. 'All-in-one'analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass Spectrometry. 2005 Sep 30;19[18]:2597-602.

67. Cuyckens F, Hurkmans R, Castro-Perez JM, Leclercq L, Mortishire-Smith RJ. Extracting metabolite ions out of a matrix background by combined mass defect, neutral loss and isotope filtration. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass Spectrometry. 2009 Jan 30;23[2]:327-32.

68. Zhang H, Ma L, He K, Zhu M. An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. Journal of mass spectrometry. 2008 Sep;43[9]:1191-200.

69. Ruan Q, Peterman S, Szewc MA, Ma L, Cui D, Humphreys WG, Zhu M. An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. Journal of mass spectrometry. 2008 Feb;43[2]:251-61.

70. Bateman KP, Castro-Perez J, Wrona M, Shockcor JP, Yu K, Oballa R, Nicoll-Griffith DA. MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass Spectrometry. 2007 May;21[9]:1485-96.

71. Zhu P, Ding W, Tong W, Ghosal A, Alton K, Chowdhury S. A retention-time-shift-tolerant background subtraction and noise reduction algorithm [BgS-NoRA] for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass Spectrometry. 2009 Jun 15;23[11]:1563-72.

72. Zhu P, Tong W, Alton K, Chowdhury S. An accurate-mass-based spectral-averaging isotope-pattern-filtering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC-MS data. Analytical chemistry. 2009 Jul 15;81[14]:5910-7.

73. Tiller PR, Yu S, Castro-Perez J, Fillgrove KL, Baillie TA. High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a 'first-line'approach for metabolite identification studies. Rapid Communications in Mass Spectrometry. 2008 Apr 15;22[7]:1053-61.

74. Zhu M, Ma L, Zhang H, Humphreys WG. Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography− high-resolution mass spectrometry and mass defect filtering. Analytical chemistry. 2007 Nov 1;79[21]:8333-41.

75. Tiller PR, Yu S, Bateman KP, Castro-Perez J, Mcintosh IS, Kuo Y, Baillie TA. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies. Rapid Communications in Mass Spectrometry. 2008 Nov 30;22[22]:3510-6.

76. Johnson CH, Gonzalez FJ. Challenges and opportunities of metabolomics. Journal of cellular physiology. 2012 Aug;227[8]:2975-81.

77. Li S, Looby N, Chandran V, Kulasingam V. Challenges in the metabolomics-based biomarker validation pipeline. Metabolites. 2024 Apr 3;14[4]:200.

78. Hewitt, S.M.; Badve, S.S.; True, L.D. Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy. Clin. Cancer Res. 2012, 18, 1524–1530.

79. Zhang, R.; Sun, X.; Huang, Z.; Pan, Y.; Westbrook, A.; Li, S.; Bazzano, L.; Chen, W.; He, J.; Kelly, T.; et al. Examination of Serum Metabolome Altered by Cigarette Smoking Identifies Novel Metabolites Mediating Smoking-BMI Association. Obesity 2022, 30, 943–952.

80. Koussiouris, J.; Looby, N.; Anderson, M.; Kulasingam, V.; Chandran, V. Metabolomics Studies in Psoriatic Disease: A Review. Metabolites 2021, 11, 375.

81. Cui, L.; Lu, H.; Lee, Y.H. Challenges and Emergent Solutions for LC-MS/MS Based Untargeted Metabolomics in Diseases. Mass Spectrom. Rev. 2018, 37, 772–792.

82. Vuckovic, D. Improving Metabolome Coverage and Data Quality: Advancing Metabolomics and Lipidomics for Biomarker Discovery. Chem. Commun. 2018, 54, 6728–6749.

83. Monteiro, M.S.; Carvalho, M.; Bastos, M.L.; Guedes De Pinho, P. Metabolomics Analysis for Biomarker Discovery: Advances and Challenges. Curr. Med. Chem. 2013, 20, 257–271.

84. Garwoli´nska, D.; Kot-Wasik, A.; Hewelt-Belka, W. Pre-Analytical Aspects in Metabolomics of Human Biofluids—Sample Collection, Handling, Transport, and Storage. Mol. Omics 2022, 19, 95–104.

85. Kirwan, J.A.; Brennan, L.; Broadhurst, D.; Fiehn, O.; Cascante, M.; Dunn, W.B.; Schmidt, M.A.; Velagapudi, V. Preanalytical Processing and Biobanking Procedures of Biological Samples for Metabolomics Research: A White Paper, Community Perspective [for "Precision Medicine and Pharmacometabolomics Task Group"—The Metabolomics Society Initiative]. Clin. Chem. 2018, 64, 1158–1182.

86. Khadka, M.; Todor, A.; Maner-Smith, K.M.; Colucci, J.K.; Tran, V.; Gau, D.A.; Anderson, E.J.; Natrajan, M.S.; Rouphae, N.; Mulligan, M.J.; et al. The Effect of Anticoagulants, Temperature, and Time on the Human Plasma Metabolome and Lipidome from Healthy Donors as Determined by Liquid Chromatography-Mass Spectrometry. Biomolecules 2019, 9, 200.

87. Hackbusch S, Morin S. Advanced LC-MS tools and software solutions to ease your metabolite identification challenges. Thermo Fisher Scientific

88. Saurina J, Sentellas S. Strategies for metabolite profiling based on liquid chromatography. Journal of Chromatography B. 2017 Feb 15;1044:103-11.

89. Ma S, Chowdhury SK. Analytical strategies for assessment of human metabolites in preclinical safety testing.

90. Guideline IH. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3 [R2]. In International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use 2009 Jun.

91. Zhu M, Zhang H, Humphreys WG. Drug metabolite profiling and identification by high-resolution mass spectrometry. Journal of Biological Chemistry. 2011 Jul 22;286[29]:25419-25.

92. Wolfender JL, Marti G, Thomas A, Bertrand S. Current approaches and challenges for the metabolite profiling of complex natural extracts. Journal of Chromatography a. 2015 Feb 20; 1382:136-64.

93. Saurina J, Sentellas S. Strategies for metabolite profiling based on liquid chromatography. Journal of Chromatography B. 2017 Feb 15; 1044:103-11.

94. Wolfender JL, Marti G, Thomas A, Bertrand S. Current approaches and challenges for the metabolite profiling of complex natural extracts. Journal of Chromatography a. 2015 Feb 20; 1382:136-64.

95. George G. a 'systems' contribution to pharmaceutical discovery and drug development. Drug Discovery. 2006:39.

96. Tollman, P, Guy, P, Altshuler, J, Flanagan,A, Steiner, M.A revolution in R&D: How genomics and genetics are transforming the biopharmaceutical industry. Boston Consulting Group, Boston, MA USA [2001] http://www.bcg.com/publicatio ns/files/eng_genomicsgenetics_rep_11_01.pdf

97. Cuperlovic-Culf M, Culf AS. Applied metabolomics in drug discovery. Expert opinion on drug discovery. 2016 Aug 2;11[8]:759-70.

98. Sanford K, Soucaille P, Whited G, et al. Genomics to fluxomics andvphysiomics — pathway engineering. Curr Opin Microbiol.2002;5:318–322.

99. Prosser G, Larrouy-Maumus G, De Carvalho LPS. Metabolomic strategies for the identification of new enzyme functions and metabolic pathways. EMBO Rep. 2014;15[6]:657–669.

100. Haycock JW. 3D cell culture: a review of current approaches and techniques. Methods Mol Biol. 2011; 695:1–15. doi:10.1007/9781-60761-984-0_1.

101. Jeong ES, Kim G, Shin HJ, et al. Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. Toxicol Appl Pharmacol. 2015;288[2]:213–222. doi: 10.1016/j.taap.2015.07.016.

102. Mattes W, Davis K, Fabian E, et al. Detection of hepatotoxicity potential with metabolite profiling [metabolomics] of rat plasma. Toxicol Lett. 2014;230[3]:467–478. doi: 10.1016/j.toxlet.2014.07.021.

103. Weiler S, Merz M, Kullak-Ublick GA. Drug-induced liver injury: the dawn of biomarkers? F1000Prime Rep. 2015; 7:34. doi:10.12703/p.

104. Zaitsu K, Hayashi Y, Kusano M, et al. Application of metabolomics to toxicology of drugs of abuse: a mini review of metabolomics approach to acute and chronic toxicity studies. Drug Metab Pharmacokinet. 2016; 31:21–26. doi: 10.1016/j.dmpk.2015.10.002.

105. Forgue P, Halouska S, Werth M, et al. NMR metabolic profiling of Aspergillus nidulans to monitor drug and protein activity. J Proteome Res. 2006; 5:1916–1923.

106. Lefort N, Brown A, Lloyd V, et al. ^{1}H NMR metabolomics analysis of the effect of dichloroacetate and allopurinol on breast cancers. J Pharm Biomed Anal. 2014; 93:77–85. doi: 10.1016/j.jpba.2013.08.017.

107. Yoshinari K, Yamashita K. Analytical chemistry for ADMET research: recent advances and future directions in LC–MS/MS and omics approaches. Drug Metab. Pharmacokinet. 2016; 31:1–2.

108. Miura M, Takahashi N. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods. Drug Metab Pharmacokinet. 2016; 31:12–20. doi: 10.1016/j.dmpk.2015.09.002.

109. Majors PD, McLean JS, Scholten JCM. NMR bioreactor development for live in-situ microbial functional analysis. J Magn Reson.2008;192[1]:159–166. doi: 10.1016/j.jmr.2008.02.014.

110. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14[2]:111–129. doi:10.1038/nrd4510.

111. Johnson SR, Lange BM. Open-access metabolomics databases for natural product research: present capabilities and future potential.Front Bioeng Biotechnol. 2015; 3:1–10. doi:10.3389/fbioe.2015.00022.

112. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012; 75:311–335.doi:10.1021/np200906s.

113. Yuliana ND, Khatib A, Choi YH, et al. Metabolomics for bioactivity assessment of natural products. Phytother Res. 2011;25[2]:157

114. Lipinski C, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev.2012;64[SUPPL.]:4–17. doi: 10.1016/j.addr.2012.09.019.

115. Cumming JG, Davis AM, Muresan S, et al. Chemical predictive modelling to improve compound quality. Nat Rev Drug Discov. 2013;12[12]:948–962. doi:10.1038/nrd4128.

116. Van De Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003;2[3]:192– 204. doi:10.1038/nrd1032.

117. Halouska S, Chacon O, Fenton RJ, et al. Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: role of D-alanine racemase. J Proteome Res. 2007;6[12]:4608–4614. doi:10.1021/pr0704332.

118. Agren R, Bordel S, Mardinoglu A, et al. Reconstruction of genomescale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol. 2012;8[5]: e1002518. doi: 10.1371/journal.pcbi.1002518.

119. Thiele I, Swainston N, Fleming RMT, et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol. 2013;31[5]:419–425. doi:10.1038/nbt.2595.

120. Folger O, Jerby L, Frezza C, et al. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol. 2011;7[501]: 501.doi:10.1038/msb.2011.35.

121. Jerby L, Ruppin E. Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin Cancer Res. 2012;18 [20]:5572–5584. doi: 10.1158/1078-0432.CCR-12-1856.

122. Kim TY, Kim HU, Lee SY. Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metab Eng. 2010;12[2]:105–111. doi: 10.1016/j.ymben.2009.05.004.

123. Dietmair S, Hodson MP, Quek L-E, et al. A multi-omics analysis of recombinant protein production in Hek293 cells.

124. Lewis NE, Schramm G, Bordbar A, et al. Large-scale in silico modelling of metabolic interactions between cell types in the human brain. Nat Biotechnol. 2010;28[12]:1279–1285. doi:10.1038/nbt.1665.

125. Quek L-E, Dietmair S, Hanscho M, et al. Reducing Recon 2 for steady-state flux analysis of HEK cell culture. J Biotechnol. 2014; 184:172–178. doi: 10.1016/j.jbiotec.2014.05.001.

126. Wishart DS. Metabolomics for drug discovery, development and monitoring. Touch Briefing-Future Drug Discov. 2006; 2006:1–3.

127. Nicholson JK, Holmes E, Kinross JM, et al. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491[7424]:384–392. doi:10.1038/nature11708.

128. Coen M, Holmes E, Lindon JC, et al. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol. 2008;21[1]:9–27. doi:10.1021/tx700335d.

129. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453[7193]:396–400. doi:10.1038/nature06882.

130. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134[5]:714–717. doi:10.1016/j. cell.2008.08.026.

131. Smith LM, Maher AD, Want EJ, et al. Large-scale human metabolic phenotyping and molecular epidemiological studies via 1H NMR spectroscopy of urine: investigation of borate preservation. Anal Chem. 2009;81[12]:4847–4856. doi:10.1021/ac9004875.

132. Jacobs A. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs. Toxicol Lett. 2009; 186:32–35. doi: 10.1016/j.toxlet.2008.08.013.